P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: A case control study

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5415-5420

  Ren, Yang Wu ^a,b   Yin, Zhi Hua ^a,b   Wan, Yan ^a,b   Guan, Peng ^a,b   Wu, Wei ^a,b   Li, Xue Lian ^a,b   Zhou, Bao Sen ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Cancer Etiology and Prevention (China Medical University)   (China)

Author keywords

Lung cancer; MDM2; P53; Polymorphism; Susceptibility

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; ASIAN; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887603866     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5415     Document Type: Article

References (38)

1. Ara S, Lee PS, Hansen MF, et al (1990). Codon 72 polymorphism of the Tp53 gene. Nucleic acids research, 18, 4961.
2. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
3. Bond GL, Hu W,Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4.
4. Brennan P (2002). Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis, 23, 381-7.
5. Caceres DD, Quinones LA, Schroeder JC, et al (2009). Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung, 187, 110-5.
6. Chene P (2003). Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer, 3, 102-9.
7. Chua HW, Ng D, Choo S, et al (2010). Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer, 10, 88.
8. Dulic V, Kaufmann WK, Wilson SJ, et al (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-23.
9. Dumont P, Leu JI, Della Pietra AC, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65.
10. Duong V, Boulle N, Daujat S, et al (2007). Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res, 67, 5513-21.
11. Eymin B, Gazzeri S, Brambilla C, et al (2002). Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene, 21, 2750-61.
12. Haupt Y, Maya R, Kazaz A, et al (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9.
13. Hu Z, Ma H, Lu D, et al (2006). Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. International journal of cancer. Int J Cancer, 118, 1275-8.
14. Jassem J, Szymanowska A, Jassem E, et al (2005). Relation between p53 codon 72 polymorphism and somatic p53 gene mutation in non-small cell lung cancer (NSCLC). Ejc Supplements, 3, 336-.
15. Jemal A, Bray F,Center MM (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
16. Jin S, Levine AJ (2001). The p53 functional circuit. J Cell Sci, 114, 4139-40.
17. Karlsson C, Helenius G, Fernandes O, et al (2012). Oestrogen receptor beta in NSCLC-prevalence, proliferative influence, prognostic impact and smoking. APMIS, 120, 451-8.
18. Kastan MB, Onyekwere O, Sidransky D, et al (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res, 51, 6304-11.
19. Lain S,Lane D (2003). Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer, 39, 1053-60.
20. Li M, Yin Z, Guan P, et al (2008). XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer, 62, 145-51.
21. Li Y, Qiu LX, Shen XK, et al (2009). A meta-analysis of Tp53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer, 66, 15-21.
22. Lind H, Zienolddiny S, Ekstrom PO, et al (2006). Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. International journal of cancer. Int J Cancer, 119, 718-21.
23. Liu D, Wang F, Guo X, et al (2013). Association between p53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in a Chinese population. Mol Biol Rep, 40, 645-9.
24. Momand J, Zambetti GP, Olson DC, et al (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-45.
25. Mooney LA, Santella RM, Covey L, et al (1995). Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epidemiol Biomarkers Prev, 4, 627-34.
26. Pesch B, Kendzia B, Gustavsson P, et al (2012). Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer, 131, 1210-9.
27. Piao JM, Kim HN, Song HR, et al (2011). p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer, 73, 264-7.
28. Sakiyama T, Kohno T, Mimaki S, et al (2005). Association of amino acid substitution polymorphisms in DNA repair genes Tp53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer, 114, 730-7.
29. Siegfried JM (2010). Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis. Cancer Prev Res (Phila), 3, 692-5.
30. Smyth JF (1996). Cancer genetics and cell and molecular biology. Is this the way forward?. Chest, 109, 125S-9S.
31. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
32. Tokiwa H, Sera N, Nakashima A, et al (1994). Mutagenic and carcinogenic significance and the possible induction of lung cancer by nitro aromatic hydrocarbons in particulate pollutants. Environ Health Perspect, 102, 107-10.
33. Wu X, Zhao H, Amos CI, et al (2002). p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst, 94, 681-90.
34. Yin Z, Su M, Li X, et al (2009). ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. J Exp Clin Cancer Res, 28, 153.
35. Zang EA,Wynder EL (1996). Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst, 88, 183-92.
36. Zhang H, Wang G,Tan W (2002). [Study on the effects of cooking oil fume condensate on the DNA integrity]. Wei Sheng Yan Jiu, 31, 238-40.
37. Zhang X, Miao X, Guo Y, et al (2006). Genetic polymorphisms in cell cycle regulatory genes MDM2 and Tp53 are associated with susceptibility to lung cancer. Human mutation, 27, 110-7.
38. Zhuo W, Zhang L, Zhu B, et al (2012). Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One, 7, e41546.